SION (Sionna Therapeutics) Beginning Cash Position: $59.41 Mil (As of Mar. 2026)


SION Sionna Therapeutics Inc SION
12 GF Score
Price $44.91
! 3 Warning Signs
View Full Analysis

What is Sionna Therapeutics Beginning Cash Position?

Sionna Therapeutics SION +4.20% 12 Beginning Cash Position is $59.41 Mil as of Mar. 2026. GuruFocus rates SION with a GF Score™ of 12/100. The stock has 3 warning signs investors should review.

Sionna Therapeutics's Beginning Cash Position for the quarter that ended in Mar. 2026 was $59.41 Mil.

Sionna Therapeutics's quarterly Beginning Cash Position increased from Sep. 2025 ($41.95 Mil) to Dec. 2025 ($51.79 Mil) and increased from Dec. 2025 ($51.79 Mil) to Mar. 2026 ($59.41 Mil).

Sionna Therapeutics's annual Beginning Cash Position declined from Dec. 2023 ($55.80 Mil) to Dec. 2024 ($39.48 Mil) and declined from Dec. 2024 ($39.48 Mil) to Dec. 2025 ($38.75 Mil).

Sionna Therapeutics Beginning Cash Position Related Terms

Sionna Therapeutics Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Sionna Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sionna Therapeutics Beginning Cash Position Chart

Sionna Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
10.28 55.80 39.48 38.75

Sionna Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 38.75 83.66 41.95 51.79 59.41
SION
12GF Score
Sionna Therapeutics Inc SION
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sionna Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $59.41 Mil mean?
Sionna Therapeutics (SION) has a Beginning Cash Position of $59.41 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Sionna Therapeutics and its competitors.
Is Sionna Therapeutics' Beginning Cash Position too high?
Sionna Therapeutics' current Beginning Cash Position is $59.41 Mil. Overall, Sionna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Sionna Therapeutics' Beginning Cash Position compare to TYRA and RAPP?
Sionna Therapeutics' Beginning Cash Position of $59.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Sionna Therapeutics and its competitors. Sionna Therapeutics's current Beginning Cash Position is $59.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sionna Therapeutics stock overvalued right now?
Sionna Therapeutics (SION) has a current Beginning Cash Position of $59.41 Mil. The current Beginning Cash Position is $59.41 Mil. Sionna Therapeutics' overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Sionna Therapeutics (SION), the current Beginning Cash Position is $59.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sionna Therapeutics Business Description

Address 21 Hickory Drive, Suite 500, Waltham, MA, USA, 02451
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefits to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
12GF Score

Get the complete analysis for SION

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$44.91
Price